<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774159</url>
  </required_header>
  <id_info>
    <org_study_id>11344</org_study_id>
    <nct_id>NCT04774159</nct_id>
  </id_info>
  <brief_title>Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk</brief_title>
  <acronym>LEADER-PAD</acronym>
  <official_title>Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial (Vanguard Phase)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The vanguard phase of the Low dose ColchicinE in pAtients with peripheral Artery DiseasE to&#xD;
      address residual vascular Risk (LEADER-PAD) trial will evaluate the feasibility of conducting&#xD;
      a full randomized trial to determine if anti-inflammatory therapy with colchicine will reduce&#xD;
      vascular events in patients with symptomatic peripheral artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LEADER-PAD trial is a randomized, double blind, multicenter pilot trial with a 2-week&#xD;
      active run-in period, comparing low dose colchicine 0.5 mg daily with placebo in patients&#xD;
      with PAD to prevent vascular events (myocardial infarction, stroke, cardiovascular deaths,&#xD;
      acute limb ischemia and vascular amputation) in patients with symptomatic peripheral artery&#xD;
      disease. The sample size for the vanguard phase is 150 patients over 1-year accrual with a&#xD;
      1-year follow-up.The primary outcome is the feasibility of recruitment. If feasibility is&#xD;
      demonstrated, patients from the vanguard phase will be rolled over into the full multicenter&#xD;
      trial if there are no major protocol modifications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind and use of similarly active and placebo tablets.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of patients recruited per center per month</measure>
    <time_frame>at least 12 months recruitment phase</time_frame>
    <description>Primary feasibility outcome for the vanguard phase is the mean number of patients recruited per center per month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients undergoing successful randomization after the active run-in period</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary feasibility outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of loss to follow-up and discontinuation rates after randomization</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary feasibility outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence rate with colchicine at 12 months of follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary feasibility outcomes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gastrointestinal toxicity that leads to treatment interruption or discontinuation, infection (e.g., pneumonia) and incident cancer</measure>
    <time_frame>12 months</time_frame>
    <description>Safety outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Adverse cardiovascular and limb events (MACE or MALE).</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Vascular Quality of Life Questionnaire-6 (VascQOL-6) at baseline, 6 and 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>Six item vascular quality of life instrument: The total score is achieved by summarizing the score on each question, resulting in a score between 6 and 24. Higher value indicates better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Standard Assessment of Global Everyday Activities (SAGEA)</measure>
    <time_frame>12 months</time_frame>
    <description>The Standard Assessment of Global Everyday Activities (SAGEA) is a 15 item tool to assess activities of daily living including higher executive function used in social situations, everyday activities and basic activities of daily living. Scores range from 0 to 24 with higher scores indicating poorer function.It is a 15 items questionnaire and the scores will range from 0, describing a very independent participant over a broad spectrum of activities, to 48 describing a very dependent participant</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Atherosclerosis of Extremities</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.5mg daily for the duration of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Colchicine-Placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.5 MG Oral Tablet</intervention_name>
    <description>Colchicine 0.5 mg tablet daily&#xD;
Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label.</description>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>Colchicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine-Placebo</intervention_name>
    <description>Colchicine-Placebo tablet</description>
    <arm_group_label>Colchicine-Placebo</arm_group_label>
    <other_name>Colchicine-Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients need to meet the following criteria for inclusion:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. History of symptomatic lower extremity PAD* with one or more high risk features:&#xD;
&#xD;
               1. symptomatic lower extremity PAD with one of the following risk factors: [&gt;1&#xD;
                  vascular bed affected by atherosclerosis, presence of diabetes, history of heart&#xD;
                  failure or lower eGFR (&lt; 60 ml/min)]&#xD;
&#xD;
               2. or prior lower extremity revascularization&#xD;
&#xD;
               3. or prior limb or foot amputation&#xD;
&#xD;
               4. or Fontaine 3 or 4 symptoms/signs&#xD;
&#xD;
          3. Written or verbal informed consent from the patient&#xD;
&#xD;
        Note:&#xD;
&#xD;
        * Lower extremity PAD is defined by one or more of the following:&#xD;
&#xD;
          1. presence of intermittent claudication and one or more of ankle/arm blood pressure&#xD;
             ratio (ABI) &lt; 0.90 or peripheral artery stenosis &gt;50% documented by angiography or&#xD;
             duplex ultrasound; or&#xD;
&#xD;
          2. a history of revascularization defined as limb bypass surgery or percutaneous&#xD;
             transluminal angioplasty of iliac or infra-inguinal arteries or extra-anatomical limb&#xD;
             bypass surgery; or&#xD;
&#xD;
          3. limb or foot amputation for macrovascular arterial vascular disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to colchicine&#xD;
&#xD;
          2. Requirement for colchicine for another clinical indication&#xD;
&#xD;
          3. Active diarrhoea&#xD;
&#xD;
          4. Creatinine Clearance &lt; 15 ml/min&#xD;
&#xD;
          5. Cirrhosis or severe chronic liver disease&#xD;
&#xD;
          6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected&#xD;
             by reliable contraception or is planning conception during the study&#xD;
&#xD;
          7. Current or planned use of any of: cyclosporine, verapamil, HIV protease inhibitors,&#xD;
             azole antifungals, or macrolide antibiotics (with the exception of azithromycin)&#xD;
&#xD;
          8. Patients who are deemed unlikely to return for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel C Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute, Hamilton, Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noel C Chan, MD</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>40727</phone_ext>
    <email>Noel.Chan@TAARI.CA</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leah Hamilton, MSc</last_name>
    <phone>902-292-6712</phone>
    <email>leah.hamilton@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Wilkinson</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>40430</phone_ext>
    </contact>
    <investigator>
      <last_name>Noel Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Noel Chan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute limb ischemia</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cardiovascular death</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

